会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Amino-and mercurio-substituted 4′,5'-dihydropsoralens and therapeutical uses thereof
    • 氨基和巯基取代的4',5'-二氢补骨脂素及其治疗用途
    • US06255324B1
    • 2001-07-03
    • US09199552
    • 1998-11-25
    • Ned D. HeindelJeffrey D. LaskinDiane E. HeckRobert D. RappMarilyn S. WhittemoreThomas E. McNeelIvan Jabin
    • Ned D. HeindelJeffrey D. LaskinDiane E. HeckRobert D. RappMarilyn S. WhittemoreThomas E. McNeelIvan Jabin
    • A61K314709
    • C07D493/04C07D311/44C07D311/56C07F3/14
    • 5′-substituted, 4′,5′-dihydropsoralen compounds (5) bearing tertiary amines (and salts thereof), quaternary ammonium moieties or organomercurial moieties are described. Also described are 2-substituted mercurimethyl-2-3-dihydro-benzofurans of forumla (7): Also reported are versatile direct syntheses through a hitherto unknown compounds such as 3-R-4,8-dimethyl-4′,5′-dihydro-5′-bromomethylpsoralen or a 3-R-4,8-dimethyl-4′, 5′-dihydro-5′-iodomethylpsoralen to prepare a structurally diverse array of partially reduced psoralens and benzofurans. The presence of a permanent ammonium charge in these psoralens precludes membrane passage and the mono-unsaturation precludes the cross-linking of nuclear DNA, thereby minimizing the mutagenic/carcinogenic side effects long associated with psoralen-derived therapies. The presence of a mercury functionality provides a reactive cell-binding group on these psoralens with unique cytotoxicity without light activation and an enhancement of cytotoxicity activity upon light activation. The invention also relates to These partially reduced and quaternized psoralens, amino-substituted psoralens, and mercurio psoralens display impressive pharmacology against PAM 212 keratinocytes, a model cell line employed as a test system to indicate epidermal cytotoxicity and cancer. The compounds of the invention also have antimicrobicidal activity useful in pharmacologic agents for mammals (e.g. the treatment of tuberculosis) as well as in controlling the growth of microorganisms on substrates and in aqueous systems.
    • 描述了含有叔胺(及其盐),季铵部分或有机聚合物部分的5'取代的4',5'-二氢补骨脂素化合物(5)。还描述了2-取代的缩水甘油二甲基-2,3-二氢 - 苯并呋喃 论坛(7):还报道了通过迄今为止未知的化合物如3-R-4,8-​​二甲基-4',5'-二氢-5'-溴甲基口服或3-R-4,8- 二甲基-4',5'-二氢-5'-碘甲基肌醇,以制备结构不同的部分还原的补骨脂素和苯并呋喃的阵列。 在这些补骨脂素中存在永久铵电荷排除了膜通过,并且单不饱和度排除了核DNA的交联,从而使与补骨脂素衍生疗法长期相关的诱变/致癌副作用最小化。 汞功能的存在在这些补骨脂素上提供了具有独特细胞毒性的反应性细胞结合基团,而没有光活化,并且在光活化时增强细胞毒性活性。 本发明还涉及这些部分还原和季铵化的补骨脂素,氨基取代的补骨脂素和补骨脂素,对PAM 212角质形成细胞,用作指示表皮细胞毒性和癌症的测试系统的模型细胞系显示令人印象深刻的药理学。 本发明的化合物还具有用于哺乳动物的药理学(例如治疗结核病)以及控制底物和水系统中的微生物生长的抗除菌活性。
    • 6. 发明授权
    • 4′-Substituted-4′,5′-dihydropsoralens and therapeutical uses thereof
    • 4'-取代-4',5'-二氢补骨脂素及其治疗用途
    • US06177424B1
    • 2001-01-23
    • US09450560
    • 1999-11-30
    • Ned D. HeindelJeffrey D. LaskinMarilyn S. WhittemoreThomas E. McNeelChristophe GuillonDiane E. HeckRobert D. Rapp
    • Ned D. HeindelJeffrey D. LaskinMarilyn S. WhittemoreThomas E. McNeelChristophe GuillonDiane E. HeckRobert D. Rapp
    • A61K3137
    • C07D493/04
    • The invention relates to 4′-substituted-4′,5′-dihydropsoralen compounds of formula(V): In the formula R is hydrogen, a halogen, CN or an acyl group; T is a halogen, CN, a carboalkoxy group NR1R2, or (N+R1R2R3)X−, R1 and R2 are independently a C1-C6 alkyl, or R1 and R2 together with the nitrogen form a 5-8 member heterocyclic ring, or when T is (N+R1R2R3)X−, R1 and R2 together with the nitrogen form a 5-8 member heterocyclic ring or heterocyclic aromatic ring; R3 is hydrogen, a C1-C12 alkyl, or, when R1 and R2 together with the nitrogen form a heterocyclic aromatic ring, R3 is a double bond within the heterocyclic aromatic ring; X− is a halide. In another embodiment, the invention relates to processes for preparing 4′-substituted-4′,5′-dihydropsoralen compounds described above. The compounds of the invention have beneficial pharmaceutical properties and can be used alone or in pharmaceutical compositions used to treat a proliferative skin disorder and to treat microbial infections in a mammal by administering to the mammal an effective amount of a compound of the invention and then irradiating the mammal with ultraviolet light.
    • 本发明涉及式(Ⅴ)的4'-取代-4',5'-二氢补骨脂素化合物:式中R是氢,卤素,CN或酰基; T是卤素,CN,烷氧羰基NR1R2或(N + R1R2R3)X-,R1和R2独立地是C1-C6烷基,或R1和R2与氮一起形成5-8元杂环,或 当T是(N + R1R2R3)X - 时,R1和R2与氮一起形成5-8元杂环或杂环芳环; R3是氢,C1-C12烷基,或当R1和R2与氮一起形成杂环芳环时,R3是杂环芳环中的双键; X-是卤化物。 在另一个实施方案中,本发明涉及制备上述4'-取代-4',5'-二氢补骨脂素化合物的方法。 本发明的化合物具有有益的药物性质,并且可以单独使用或用于治疗增殖性皮肤病症的药物组合物和通过向哺乳动物施用有效量的本发明化合物然后照射而治疗哺乳动物的微生物感染 哺乳动物用紫外线照射。